Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)

NCT02681549 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Melanoma
Non-small Cell Lung Cancer
Brain Metastasis

Interventions

DRUG: Pembrolizumab plus Bevacizumab

Sponsor

Yale University

Collaborators

[object Object]
[object Object]